Citations for: Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e, 2011 > Estrogens and Progestins. Laurence L. Brunton, Bruce A. Chabner, Björn C. Knollmann.

Entry Type
Name
Value
Parent Entry
Pharmacology Data Field
Serum Protein Binding
97% bound. Mainly to serum albumin. No binding to SHBG, but induces SHBG synthesis.
Ethinyl Estradiol (API)
Pharmacology Data Field
Androgen Receptor Activity
Partial antagonist (about 30% activity of cyproterone acetate)
Drospirenone (API)
Pharmacology Data Field
Mineralocorticoid Receptor Activity
Antagonist (antimineralocorticoid or aldosterone antagonist). Agonist reports vary: "weak" (Africander) to "strong" (Bartsch).
Drospirenone (API)
Pharmacology Data Field
Elimination Half-Life (t1/2)
7-8 h (Stanczyk, Goodman & Gilman)
4.8 - 12.8 h (Toxnet)
Norethindrone (API)
Pharmacology Data Field
Serum Protein Binding
> 95%, 61% to albumin, 36% to SHBG
Norethindrone (API)
Pharmacology Data Field
Elimination Half-Life (t1/2)
12-14 h, 16-18 h
Gestodene (API)
Metabolites
Estrone
N/A
Metabolites
Estriol
N/A
Metabolites
Other Estradiol Metabolites
N/A
Pharmacology Data Field
Progesterone Receptor Activity
Partial agonist and antagonist
Ulipristal Acetate (API)
Toxicology Data Field
Side Effects
Headache, abdominal pain, nausea, dysmenorrhea, fatigue, and dizziness.
Ulipristal Acetate (API)
Pharmacology Data Field
Glucocorticoid Receptor Activity
Antagonist
Ulipristal Acetate (API)
Pharmacology Data Field
Serum Protein Binding
60% to albumin, 38% to SHBG.
Estradiol (API)